Evan Vucci / AP

It's looking like President Trump's executive order on drug prices may not have much bite after all.

Kaiser Health News and Politico report that much of the work is being led by Joe Grogan, an Office of Management and Budget official who used to be a lobbyist for Gilead Sciences — the company that helped set off the drug price debate when it charged $1,000 per pill for its hepatitis C drugs. And some of the solutions the task force has discussed are pretty industry-friendly — like giving drugs longer patent protections in foreign markets, a policy that critics say would make them more expensive.

Why it matters: Trump campaigned on populist promises to lower drug prices and has been pushing his team to propose executive actions he can take on his own. These early signs suggest that his executive actions may fall pretty far short of his campaign promises.

Go deeper

Child care crisis is denting the labor market

Reproduced from Pew Research Center; Chart: Axios Visuals

New data from the Pew Research Center shows that parents are being hit especially hard by the coronavirus pandemic, and as far as job losses go, mothers and fathers are faring equally poorly.

Why it matters: Economists have been warning for months that the pandemic could do long-term damage to the economy as people remain unemployed for longer stretches of time.

Mike Allen, author of AM
1 hour ago - Politics & Policy

Trump-Biden venom on display during final debate

Photos: Brendan Smialowski/AFP via Getty Images; Jim Watson/AFP via Getty Images

Joe Biden twice referred to President Trump as "this guy," and Trump called the former vice president's family "like a vacuum cleaner" for foreign money.

Why it matters: The personal venom — during Thursday's final presidential debate, in Nashville — was a reminder that even during a more normal debate, nothing this year is normal.

Dave Lawler, author of World
3 hours ago - World

Special report: Trump's hopes of nuclear deal with Putin come down to the wire

Illustration: Lazaro Gamio/Axios

A surprise offer from Vladimir Putin has the U.S. and Russia once again circling a potential pre-election nuclear deal.

The big picture: The last treaty constraining the U.S. and Russia, New START, is due to expire on Feb. 5, 2021, two weeks after the next U.S. presidential inauguration. For the first time since the height of the Cold War, the nuclear guardrails could come off.